2024
Tackling the excesses of pharmaceutical marketing and promotion
Gupta R, Ramachandran R, Ross J. Tackling the excesses of pharmaceutical marketing and promotion. The BMJ 2024, 385: e076797. PMID: 38772671, DOI: 10.1136/bmj-2023-076797.Peer-Reviewed Original Research
2021
Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs
Miller JE, Mello MM, Wallach JD, Gudbranson EM, Bohlig B, Ross JS, Gross CP, Bach PB. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs. JAMA Network Open 2021, 4: e217075. PMID: 33950209, PMCID: PMC8100865, DOI: 10.1001/jamanetworkopen.2021.7075.Peer-Reviewed Original ResearchConceptsFDA approvalHigh-income countriesDrug approvalIncome countriesNovel drugsDrug Administration (FDA) drug approvalsRegulatory agency websitesCross-sectional analysisProportion of drugPrimary outcomeFDA drug approvalsProportion of countriesDrug trialsMAIN OUTCOMEUS FoodClinical researchCountry income levelLow-income countriesMarketing approvalTrialsGoogle ScholarDrugsDrug companiesApprovalMedian
2018
Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS
Kim J, Ross JS, Kapczynski A. Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS. JAMA 2018, 319: 21-22. PMID: 29117365, DOI: 10.1001/jama.2017.16477.Commentaries, Editorials and Letters
2017
High Costs of FDA Approval for Formerly Unapproved Marketed Drugs
Hakim A, Gupta R, Ross JS. High Costs of FDA Approval for Formerly Unapproved Marketed Drugs. JAMA 2017, 318: 2181-2182. PMID: 29131905, DOI: 10.1001/jama.2017.16481.Commentaries, Editorials and LettersPost‐marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross‐sectional study
Zeitoun J, Baron G, Vivot A, Atal I, Downing NS, Ross JS, Ravaud P. Post‐marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross‐sectional study. International Journal Of Cancer 2017, 142: 414-423. PMID: 28929484, DOI: 10.1002/ijc.31061.Peer-Reviewed Original ResearchConceptsPost-marketing trialsPrimary outcomeNovel anticancer agentsPost-market researchAnticancer agentsSupplemental indicationsCross-sectional studyPost-marketing researchEuropean Medicines AgencyCross-sectional analysisTypes of cancerPost-market trialClinical endpointsHematologic malignanciesKidney cancerSolid cancersSurrogate endpointsUS FoodDrug AdministrationMedicines AgencyOverall populationCancerTrialsPublication rateOutcomesUS drug marketing: how does promotion correspond with health value?
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value? The BMJ 2017, 357: j1855. PMID: 28465309, DOI: 10.1136/bmj.j1855.Peer-Reviewed Original Research
2016
Characterisation of trials where marketing purposes have been influential in study design: a descriptive study
Barbour V, Burch D, Godlee F, Heneghan C, Lehman R, Perera R, Ross JS, Schroter S. Characterisation of trials where marketing purposes have been influential in study design: a descriptive study. Trials 2016, 17: 31. PMID: 26792624, PMCID: PMC4720997, DOI: 10.1186/s13063-015-1107-1.Peer-Reviewed Original ResearchConceptsMedian numberDrug trialsGeneral medical journalsComposite primary outcome measureStudy designTerms of blindingPrimary outcome measureTrials of drugsHigh-impact general medical journalsKey trial characteristicsIndustry-funded trialsMedical journalsAdverse eventsCategories of trialsTrial characteristicsOutcome measuresStudy populationSafety outcomesBlinded researcherStudy characteristicsDescriptive studyTrial documentationTrialsSignificant differencesMarketing trials
2014
Marketing to Physicians in a Digital World
Manz C, Ross JS, Grande D. Marketing to Physicians in a Digital World. New England Journal Of Medicine 2014, 371: 1857-1859. PMID: 25390738, DOI: 10.1056/nejmp1408974.Commentaries, Editorials and LettersRestricting Interactions With Industry to Promote Evidence-Based Prescribing
Ross JS. Restricting Interactions With Industry to Promote Evidence-Based Prescribing. JAMA Internal Medicine 2014, 174: 1290-1290. PMID: 24912054, DOI: 10.1001/jamainternmed.2014.1862.Commentaries, Editorials and Letters
2012
Avoidance of Generic Competition by Abbott Laboratories' Fenofibrate Franchise
Downing NS, Ross JS, Jackevicius CA, Krumholz HM. Avoidance of Generic Competition by Abbott Laboratories' Fenofibrate Franchise. JAMA Internal Medicine 2012, 172: 724-730. PMID: 22493409, PMCID: PMC3636774, DOI: 10.1001/archinternmed.2012.187.Commentaries, Editorials and Letters
2011
Study of Neurontin: Titrate to Effect, Profile of Safety (STEPS) Trial: A Narrative Account of a Gabapentin Seeding Trial
Krumholz SD, Egilman DS, Ross JS. Study of Neurontin: Titrate to Effect, Profile of Safety (STEPS) Trial: A Narrative Account of a Gabapentin Seeding Trial. JAMA Internal Medicine 2011, 171: 1100-1107. PMID: 21709111, PMCID: PMC3319750, DOI: 10.1001/archinternmed.2011.241.Peer-Reviewed Original Research
2010
Physician Attitudes Toward Industry: A View Across the Specialties
Korenstein D, Keyhani S, Ross JS. Physician Attitudes Toward Industry: A View Across the Specialties. JAMA Surgery 2010, 145: 570-577. PMID: 20566978, PMCID: PMC2891545, DOI: 10.1001/archsurg.2010.75.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdultAttitude of Health PersonnelConflict of InterestCross-Sectional StudiesDrug IndustryEquipment and SuppliesEthics, MedicalFemaleGeneral SurgeryGift GivingHumansInterprofessional RelationsMaleMarketingMiddle AgedMultivariate AnalysisNew York CityPractice Patterns, Physicians'Surveys and QuestionnairesTotal Quality Management
2008
The ADVANTAGE seeding trial: a review of internal documents.
Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Annals Of Internal Medicine 2008, 149: 251-8. PMID: 18711155, DOI: 10.7326/0003-4819-149-4-200808190-00006.Peer-Reviewed Original Research